Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Plos One|April 25, 2014
A method to assess target gene involvement in angiogenesis in vitro and in vivo using lentiviral vectors expressing shRNAWayne Blosser, Eliza Vakana, Lisa V Wyss, et al.
Journal of Deaf Studies and Deaf Education|January 14, 2026
Examining signed language challenges of early- and late-exposed deaf childrenDavid Quinto-Pozos, James P McCann, Maya Athreya, et al.
Drug Discovery Today|September 5, 2012
High-content multiplexed tissue imaging and quantification for cancer drug discoveryBeverly L Falcon, Julie Stewart, Scharri Ezell, et al.
International Journal of Cancer|January 18, 2003
Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17qBrad Stone, Michèl Schummer, Pamela J Paley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human NeuroblastomaCaitlin D Lowery, Alle B VanWye, Michele Dowless, et al.
Molecular Cancer Therapeutics|December 23, 2011
Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesisGiulio Francia, Yuval Shaked, Kae Hashimoto, et al.
Plos One|March 9, 2016
Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic MalignanciesSheng-Bin Peng, Xiaoyi Zhang, Donald Paul, et al.
Journal of Hematology & Oncology|April 30, 2013
Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibitionBeverly L Falcon, Belinda O'Clair, Don McClure, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 2, 2013
Increased expression of CYP24A1 correlates with advanced stages of prostate cancer and can cause resistance to vitamin D3-based therapiesMounia Tannour-Louet, Shaye K Lewis, Jean-François Louet, et al.
Molecular Cancer Therapeutics|December 16, 2014
Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic modelsSheng-Bin Peng, Xiaoyi Zhang, Donald Paul, et al.
Pageof 3